source
- Novo presents low-dose CagriSema data showing competitiveness ahead of approval decisionNovo used its capital markets day in London to unveil new low-dose data for its experimental metabolic therapy CagriSema. The data indicated that CagriSema performed comparably to Eli Lilly's Moun…
- FDA issues rule to allow non-animal testing methods for drug safetyFDA issued a direct final rule that updates its regulations to clarify that non-animal methods may be used for safety testing of drugs and biological products before they are tested in humans. The…